Published • loading... • Updated
PreludeDx Announces the Publication of the Independent Validation of the AidaBREAST® test in npj Breast Cancer
Summary by Newswise
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
PreludeDx Announces the Publication of the Independent Validation of the AidaBREAST® test in npj Breast Cancer
Prelude Corporation (PreludeDx(r)), a leader in precision diagnostics for early-stage breast cancer, today announced the publication of results from the first independent validation of AidaBREAST(r), a novel multi-omic biosignature developed to predict a woman's 10-year risk of locoregional recurrence and her individualized benefit from adjuvant radiation therapy following breast-conserving surgery.
·Charlottesville, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
